TC Energy Corp
TRP
TELUS Corp
T
Power Corporation of Canada
POW
Bank of Nova Scotia
BNS
BCE Inc
BCE
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.